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ABSTRACT 111 
Arhinia, or absence of the nose, is a rare malformation of unknown etiology that is often 112 
accompanied by ocular and reproductive defects. Sequencing of 38 arhinia subjects from 36 113 
independent families revealed that 86% of independent subjects harbor a missense mutation in a 114 
constrained ATPase domain of SMCHD1. Mutations in SMCHD1 also cause 115 
facioscapulohumeral muscular dystrophy type 2 (FSHD2) via a complex trans-acting loss-of-116 
function epigenetic mechanism. Arhinia subjects had comparable DNA hypomethylation 117 
patterning to FSHD2 subjects, and CRISPR/Cas9 editing of smchd1 in zebrafish yielded arhinia-118 
relevant phenotypes. Mutations in SMCHD1 thus contribute to remarkably distinct phenotypic 119 
spectra from craniofacial and reproductive disorders to muscular dystrophy, which we speculate 120 
to be consistent with oligogenic mechanisms resulting in pleiotropic outcomes.  121 
  122 
Arhinia, or the complete absence of the external nose, is a rare congenital malformation with 123 
only 80 patients without holoprosencephaly reported in the past century (see Supplementary 124 
Table 1 for all previous reports). This severe craniofacial dysmorphism can be isolated or 125 
accompanied by other craniofacial defects including coloboma, anophthalmia, cataracts, 126 
nasolacrimal duct atresia, choanal atresia, and cleft palate (Fig. 1). Seventeen patients with 127 
arhinia and ocular defects have been reported with coexistent reproductive failure secondary to 128 
hypogonadotropic hypogonadism, a triad called Bosma arhinia microphthalmia syndrome 129 
(BAM; OMIM 603457)1. In the neonatal period, patients with arhinia are at high risk for 130 
respiratory distress, difficulty feeding, and sepsis (as a complication of reconstructive surgery), 131 
but those surviving infancy generally demonstrate normal cognitive development with few 132 
functional challenges limited to vision loss, the stigma of facial deformities, and osteoporosis 133 
and infertility due to hypogonadism. The rarity of these malformations and cross-disciplinary 134 
nature of its comorbid conditions have limited systematic efforts to catalog its associated 135 
phenotypes, although these comorbidities suggest that genetic factors influencing this condition 136 
may have broader developmental implications.   137 
 138 
Genetic studies of arhinia have been limited to karyotype analysis, chromosomal microarray, and 139 
candidate gene approaches targeting genes related to neural crest cells (NCC) or craniofacial 140 
placodal development; to date, no causal locus has been identified. Phenocopies are likewise 141 
scarce; homozygous null mutations in Pax6 arrest nasal placodogenesis in mice2 and cause 142 
rudimentary or malformed noses in humans3-5. However, heterozygous and homozygous null 143 
mutations in PAX6 cause aniridia and severe structural brain abnormalities, respectively, that are 144 
not observed in individuals with arhinia3-5. We formed an international consortium to investigate 145 
the genetic etiology of arhinia and its associated comorbidities and aggregated all available cases 146 
across sites. We sequenced 38 individuals with arhinia from 36 independent families as well as 147 
51 family members without ahrinia. Through family-based analyses of de novo mutations and 148 
genome-wide burden analysis supported by functional studies, we report that rare missense 149 
variants in SMCHD1 represent the predominant single gene contributor to arhinia. Notably, 150 
SMCHD1, an epigenetic repressor, has also been implicated in a rare, complex oligogenic form 151 
of muscular dystrophy (fascioscapulohumeral muscular dystrophy; FSHD2, OMIM 158901). 152 
Methylation studies in arhinia patient samples, as well as complementation testing of arhinia 153 
variants in a zebrafish model, revealed a common direction of allele effect in both arhinia and 154 
FSHD2, a surprising observation considering the striking difference in phenotypes. Given the 155 
known oligogenic architecture of FSHD2, these data argue that loss-of-function at the SMCHD1 156 
locus contributes to the diverse manifestations of arhinia, BAM, and FSHD2, likely through 157 
interaction with other genomic loci. 158 
 159 
RESULTS 160 
Samples, phenotypes, and epidemiology of arhinia 161 
We established a large international consortium and aggregated all available biospecimens and 162 
clinical data to identify the genetic cause of arhinia. This cohort encompassed 24% of all 80 163 
previously reported subjects and an additional 19 new subjects (Supplementary Table 1), 164 
facilitating a relatively comprehensive picture of the phenotypic spectrum of arhinia 165 
(Supplementary Table 2). All subjects had complete arhinia, almost universally accompanied 166 
by abnormalities of the surrounding craniofacial structures, including high-arched or cleft palate, 167 
absent paranasal sinuses, hypoplastic maxilla, nasolacrimal duct stenosis or atresia, and choanal 168 
atresia (Fig. 1), and 44% of subjects also had dysmorphic pinnae or low-set ears. Ocular 169 
phenotypes included anophthalmia or microphthalmia (69%), uveal coloboma (76%), and 170 
cataract (47%), while at least six subjects had normal eye anatomy and vision. Among the 28 171 
subjects in whom the reproductive axis could be assessed (19 male; 9 female), all demonstrated 172 
reproductive failure due to hypogonadotropic hypogonadism (HH), and all seven subjects with 173 
available brain MRI data presented with absent olfactory structures on imaging; both 174 
presentations are hallmark clinical signs of gonadotropin releasing hormone (GnRH) deficiency 175 
and anosmia (Kallmann syndrome; OMIM 308700). Twenty-four of these 28 individuals also 176 
had ocular defects, indicating that 86% of arhinia subjects that could be assessed met diagnostic 177 
criteria for BAM.  178 
 179 
Sequencing and gene discovery 180 
To investigate the contribution of rare coding variants to arhinia, we used whole-exome 181 
sequencing (WES) in an initial cohort of 22 probands: 9 subjects with available DNA from 182 
families of varying pedigree configurations and 13 subjects with no familial samples available 183 
(see Supplementary Fig. 1). Concurrent with WES, whole-genome sequencing (WGS) was 184 
performed in four members of a previously reported multiplex family that included a proband 185 
affected with arhinia, an affected sister, an unaffected brother and father, a mother with anosmia 186 
and subtle nasal and dental anomalies, a maternal half-aunt with arhinia, and a maternal 187 
grandmother who also had mild nasal and dental anomalies (Supplementary Fig. 1; family 188 
O)6,7. These analyses identified rare missense variants in SMCDH1 in 81.8% of independent 189 
probands (Table 1), none of which were present in the Exome Aggregation Consortium (ExAC) 190 
database of 60,706 healthy individuals with WES8,9. Among the eight WES samples with 191 
familial information and an observed SMCHD1 mutation, we confirmed 3 to have arisen de novo 192 
and additional 4 samples where the mutation was not observed in available family samples 193 
(parent or siblings), while in one subject (family T), the variant was inherited from a father with 194 
no craniofacial abnormalities but who carried a clinical diagnosis of muscular dystrophy. To 195 
formally test whether the observed allelic distribution in arhinia subjects represented a significant 196 
accumulation of rare missense variants, we compared the rare mutation burden among 22,445 197 
genes in the arhinia subjects to the WES data from ExAC (minor allele frequency [MAF] 198 
<0.1%). Powered by the size of our aggregate cohort, we found that SMCHD1 was the only gene 199 
that achieved genome-wide significance for a rare mutation burden (p = 2.9x10-17, Fig. 2).  200 
 201 
All of the variants identified in this initial cohort were localized to six of the 48 exons that 202 
comprise SMCHD1 (exons 3, 8, 9, 10, 12, 13; Ensemble transcript ENST00000320876). Based 203 
on this narrow distribution, we performed targeted sequencing of these exons in an additional 13 204 
subjects and discovered rare SMCHD1 missense mutations in 9 of these probands. WES on the 205 
SMCHD1 negative samples identified additional rare missense mutations in three of the four 206 
probands remaining, all localized to exons adjacent to the initial six screened in the targeted 207 
assays (exons 5,6,11). In these collective analyses (WES, WGS, targeted sequencing), 86.1% 208 
(31/36) of independent arhinia probands had a rare missense variant in SMCHD1 (Table 1), and 209 
all sporadic subjects with complete trios harbored a de novo variant (n = 10). In an additional 210 
four multigenerational, multiplex families (O, T, AB, AH) harbored rare missense alleles in 211 
SMCHD1 that segregated with variable phenotypes such as anosmia, asymmetric nares, 212 
abnormal dentition, nasal hypoplasia, hypogonadism, and muscular dystrophy, suggesting 213 
incomplete penetrance, variable expressivity, and possible pleiotropy associated with alterations 214 
of SMCHD1 (Supplementary Fig. 1a).  215 
 216 
SMCHD1 is among the most highly constrained genes in the genome, suggesting strong 217 
intolerance to loss-of-function variation (evolutionary constraint pLI = 1.00)10, with an estimated 218 
combined prevalence of 1 in 10,000 heterozygous null individuals in ExAC. However, the gene 219 
does not show particularly strong intolerance to missense variation (81% of expected missense 220 
variants observed; p = 0.016). The localization of all arhinia-specific SMCHD1 mutations to 221 
exons 3-13 led us to probe further the distribution of rare missense variants observed in ExAC 222 
across this gene. Analyses of regional constraint among the individual exons and critical domains 223 
in the protein revealed strong evidence of constraint against missense variation in the 5’ region 224 
of the gene, including exons 1-19 encompassing an ATPase domain (61% of expected missense 225 
variants observed; χ2 = 32.40; p = 1.26x10-8), whereas there was no evidence of in the region 226 
including exons 20-48, encompassing an SMC-hinge domain (95% of expected missense 227 
variants observed; χ2  = 0.86; p = 0.36; Fig. 3). This observation of strong regional constraint is 228 
consistent with the increased burden of rare SMCHD1 alleles in arhinia subjects, and suggests 229 
that these alleles may impede protein function.  In silico prediction of protein pathogenicity from 230 
the Combined Annotation Dependent Depletion (CADD) database revealed that the 19 arhinia-231 
specific SMCHD1 variants were more deleterious than all rare, nonsynonymous variants in 232 
ExAC (MAF < 0.01%, ExAC n = 378, p= 8.27x10-5; Supp Figure 2). Importantly, there are 20 233 
rare missense variants in ExAC between exons 3-13 with CADD scores exceeding the median 234 
arhinia score (16.91), further supporting our speculation that deleterious SMCHD1 variant are 235 
not fully penetrant, and such variants alone may not be sufficient to manifest arhinia.  236 
Mutational overlap between arhinia and a rare form of muscular dystrophy 237 
SMCHD1 encodes a large protein (2007 amino acids) containing a 5’ functional GHKL-type 238 
ATPase domain11 and a 3’ SMC-hinge domain (for dynamic DNA binding) that serves as an 239 
epigenetic regulator of both autosomal and X-linked genes12-15. The discovery of an association 240 
between this gene and craniofacial development was unexpected since mutations in SMCHD1 241 
are associated with FSHD2, a rare oligogenic form of muscular dystrophy. In FSHD2, 242 
heterozygous loss of SMCHD1 repressor activity, in combination with a permissive D4Z4 243 
haplotype on chromosome 4 (4q35), allows for the ectopic expression of the DUX4 protein 244 
which is cytotoxic to skeletal muscle16. The distribution of mutations in FSHD2 span the entire 245 
gene and include missense and truncating variants, whereas all variants observed in arhinia 246 
subjects were missense variants clustered tightly around the GHKL-type ATPase domain (Fig. 247 
3), which is thought to be critical to the controlled release of DNA bound by SMCHD117. 248 
However, we were surprised to find several previously reported FSHD2-specific missense 249 
mutations localized to exons 3-13, and one of these FSHD2 variants was also detected in the 250 
arhinia cohort (G137E in subject #AG1)18. At present, neither subject has features of both 251 
disorders, indicating that either these phenotypes have arisen by divergent mechanisms or are 252 
influenced by additional loci.   253 
 254 
Methylation profiling and protein expression in arhinia and FSHD2 subjects with 255 
SMCHD1 variants  256 
Haploinsufficiency and dominant negative loss-of-function models have both been invoked in 257 
FSHD2 for SMCHD1 mutations that disrupt the open reading frame (nonsense, indel, or splice-258 
site) or preserve it (missense), respectively18. In both models, loss of SMCHD1 repressive 259 
activity manifests as a decrease in DNA methylation at SMCHD1 binding sites11,16,19,20.  Clinical 260 
testing for FSHD2 relies on methylation profiling of two of these binding sites, the FSHD-261 
associated 4q35 D4Z4 macrosatellite array and the highly homologous 10q26 D4Z4 array21,22.  262 
To pursue evidence of mechanistic overlap between arhinia and FSHD2, we quantified 4q35 263 
D4Z4 methylation in 23 arhinia subjects (19 with SMCHD1 rare missense variants) and 22 264 
family members: 4 with SMCHD1 rare missense variants, including two with anosmia, one with 265 
a hypoplastic nose, and one with symptoms of muscular dystrophy, while the remaining 19 266 
family members were SMCHD1 mutation-negative.  Remarkably, 73.6% (14 of 19) of arhinia 267 
subjects with an SMCHD1 variant had D4Z4 hypomethylation characteristic of FSHD2 (Fig. 4; 268 
Supplementary Table 4), while all 4 arhinia subjects without a rare missense variant in 269 
SMCHD1 had normal methylation patterns. Two of the four family members harboring an 270 
SMCHD1 variant also displayed D4Z4 hypomethylation, while 17 of the 19 family members 271 
without a rare SMCHD1 variant had normal methylation patterns. These data confirmed that 272 
arhinia-specific mutations in SMCHD1 were associated with the same methylation patterning at 273 
D4Z4 as seen in FSHD2, illuminating that two completely distinct phenotypes can arise from 274 
alterations to the same genetic locus, and indeed the same alleles, proposing that similar loss-of-275 
function genetic mechanisms may result in distinct phenotypes. We thus turned to in vivo 276 
modeling to probe the functional impact of SMCHD1 alterations in animal models. 277 
 278 
In vivo modeling studies of SMCHD1 alterations 279 
To test directly the effect of missense alleles in arhinia patients, and to provide biological 280 
evidence for their pathogenicity, we evaluated phenotypes relevant to isolated arhinia and BAM 281 
in zebrafish (Danio rerio) larvae. While there is no zebrafish structure credibly homologous to 282 
the human nose, facial cartilage patterning is one possible proxy for human craniofacial 283 
architecture23. Zebrafish eye development is also highly conserved between species, making the 284 
zebrafish a robust model for the study of microphthalmia gene candidates identified in human 285 
studies24-26. D. rerio further possesses at least two of the three GnRH paralogs that exist in 286 
humans, and the processes by which neurons proliferate, migrate, and maintain the 287 
neuroendocrine axis are thought to be largely conserved between humans and teleosts27-29. 288 
Importantly, the zebrafish genome harbors a single SMCHD1 ortholog (49% identical, 67% 289 
similar to human), and the N-terminal encoding the ATPase domain is conserved between the 290 
two species (Supplementary Fig. 2). 291 
 292 
We designed two non-overlapping morpholino (MO) antisense oligonucleotides targeting splice 293 
donor sites of two different exons within the smchd1 genomic region encoding the ATPase 294 
domain (e3i3 and e5i5 targeting exons 3 and 5, respectively). The e3i3 or e5i5 smchd1 MOs 295 
(3ng, 6ng, and/or 9 ng/embryo) were injected into embryo batches at the one-to-two cell stage 296 
and larvae were evaluated quantitatively for aberrant cartilage patterning, ocular development, 297 
and reproductive axis integrity between 1.5 and 3 days post-fertilization (dpf) (Fig. 5a).  All 298 
morphant batches demonstrated a dose-dependent decrease in ethmoid plate width (Fig. 5a, 5b, 299 
Supplementary Fig. 3a); a dose-dependent increase in ceratohyal arch angle and delayed (or 300 
absent) development of ceratobranchial arch pairs (Fig. 5a, 5c, 5d, Supplementary Fig. 3b-c) 301 
and microphthalmia (tested at a 9 ng dose), all of which demonstrate alterations to phenotypes of 302 
relevance to human craniofacial and ear development. Moreover, whole-mount immunostaining 303 
of MO-injected embryos with a pan-GnRH antibody followed by ventral imaging revealed a 304 
prominent phenotype.  The morphant olfactory bulbs and hypothalami were intact; however, the 305 
average projection length of the terminal nerve, where GnRH3 neurons reside, was reduced by 306 
45% compared with controls (p < 0.0001; n = 20 embryos/batch; 2 measurements/embryo, 307 
repeated with masked scoring; Fig. 5g).  The observed cartilage, eye, and GnRH phenotypes 308 
were unlikely to be non-specific as each defect was reproduced with both MOs tested, but co-309 
injection of MO and full-length human wild-type (WT) SMCHD1 mRNA rescued each 310 
phenotype significantly (Fig. 5). To further confirm these findings and rule out artifacts of MO 311 
suppression or toxicity, we targeted the smchd1 locus using CRISPR/Cas9 genome-editing to 312 
generate small insertions and deletions of the coding sequence (Supplementary Fig. 4); each of 313 
the craniofacial, ocular, and GnRH defects observed in the two morphant models were 314 
significantly recapitulated in F0 mutants (Figure 5, Supplementary Fig. 5).   315 
 316 
Having established credible quantitative in vivo assays, we tested both gain and loss of function 317 
paradigms. Injection of either full-length human WT SMCHD1 mRNA or equivalent doses of 318 
full-length human mRNA bearing three different recurrent arhinia-associated variants (S135C, 319 
L141F, and H348R) into zebrafish embryos independent of MO did not yield appreciable 320 
craniofacial phenotypes (Supplementary Fig. 6). Moreover, augmented doses of mutant mRNA 321 
alone (up to 100 pg) or combinatorial injections of mutant and WT mRNA (100 pg each) was 322 
likewise unremarkable arguing that, at least in the context of this assay, a gain-of-function 323 
biochemical mechanism is unlikely. Given that suppression of smchd1 reproduced the three 324 
hallmark phenotypes of BAM, we next tested a loss of function paradigm through in vivo 325 
complementation. Focusing on our most sensitive assay, the quantitatively defined reduced 326 
projection of the GnRH-positive terminal nerve, we co-injected either: (1) full-length human WT 327 
SMCHD1 mRNA; (2) human message encoding each of the three variants identified recurrently 328 
in arhinia subjects (S135C, L141F, or H348R); or (3) human message encoding a missense 329 
variant (P690S) that causes FSHD216 with the e5i5 MO. Full-length human WT SMCHD1 330 
mRNA, but none of the mutant mRNAs associated with arhinia or FSHD2, rescued the GnRH 331 
phenotype (Fig. 5g).  Complementation of message with a common, and presumably benign, 332 
variant from ExAC (V708I; rs2270692) also rescued the phenotype, supporting assay specificity. 333 
The likely mode of action of the discovered arhinia alleles in this assay is thus loss-of-function, 334 
and we find no foundational differences between the arhinia-specific alleles and the alleles 335 
discovered in FSHD2 patients with respect to direction of effect. 336 
 337 
Next, we performed CRISPR/Cas9 genome editing on mouse embryos using a guide RNA 338 
spanning the boundary between exon 3 and intron 3 of mouse Smchd1. The 63 embryos 339 
recovered after two zygotic injection sessions displayed a range of variants including WT, 340 
homozygous knock-ins of L141F (KI), homozygous knock-outs (KO), compound heterozygotes 341 
(L141F/null), and complex compound heterozygous deletions (Supplementary Table 3). 342 
Unfortunately, multiple attempts to generate non-mosaic L141F heterozygous embryos (WT/KI), 343 
akin to what is observed in arhinia subjects, using WT repair templates at equimolar ratio to the 344 
mutant repair templates were unsuccessful. Non-mosaic homozygous KO, homozygous KI, and 345 
compound heterozygous KO/KI embryos were examined using optical projection tomography30 346 
at 13.5 days post-conception (dpc) and we observed no morphological or growth anomalies 347 
(Supplementary Fig. 5). These results in mouse embryos do not support a simple 348 
haploinsufficiency, or indeed null, mechanism causing arhinia but are consistent with previous 349 
studies in mice in which Smchd1 knockdown did not cause craniofacial defects12,31, though 350 
complete knockout of the gene is not viable, and support the notion from the human genetic data 351 
that alteration to a single copy of SMCHD1 alone may not be sufficient to induce pathology in 352 
mammals.  353 
 354 
Protein modeling and human expression studies  355 
We investigated the potential impact of these arhinia-specific mutations on SMCHD1 protein 356 
structure. The protein structure of the N-terminal region of SMCHD1, where the constrained 357 
GHKL-type ATPase domain resides, is unknown. However, the crystal structure of heat shock 358 
protein 90 (Hsp90), a member of the GHKL-ATPase protein family found in yeast, is known 359 
(PDB: 2CG9), and a recent small-angle X-ray scattering study demonstrated that the ATPase 360 
domains of these two proteins are similar in structure11. We generated a structural model of the 361 
N-terminal region of SMCHD1 with Phyre232 (Fig. 6A), with residues mutated in arhinia and 362 
FSHD2 highlighted. The top ranking templates identified were Hsp90 structures, covering 363 
residues 115-573, although the strongest homology is from approximately residues 120-260. The 364 
structural model indicates that the arhinia-specific mutations tend to cluster on the protein 365 
surface, suggesting that residues mutated in arhinia may be part of an interaction surface.  This 366 
hypothesis is independently supported by sequence-based predictors of solvent accessibility (Fig. 367 
6B), which reveal a significant tendency for arhinia mutations to be exposed on the protein 368 
surface.   369 
 370 
Finally, as an initial step towards understanding the pathogenic mechanism of arhinia, we 371 
measured SMCHD1 protein levels and performed RNAseq on lymphoblastoid cell lines (LCLs) 372 
from 23 total subjects: 10 subjects with arhinia harboring presumably pathogenic SMCHD1 373 
variants, 11 unaffected family members without SMCHD1 mutations, and two family members 374 
with a mutation in SMCHD1 and anosmia or a hypoplastic nose (AH3 and AH5, respectively). In 375 
the arhinia subjects, SMCHD1 protein levels appeared to be preserved (on average) in LCLs 376 
from subjects with an SMCHD1 variant compared to controls using two different anti-Smchd1 377 
antibodies (Bethyl A302-872A-M and Abcam ab122555; Supplementary Fig. 9).  RNAseq 378 
analyses incorporated affection status and familial relationships, and differential expression 379 
analyses following permutation testing revealed a relatively uniform distribution of p-values 380 
compared to expectations. We first compared overall expression changes in SMCHD1 and allele-381 
specific expression differences of SMCHD1 transcripts in arhinia probands. After confirming all 382 
mutations in the expressed transcripts that were observed in the DNA analyses, we found that 383 
arhinia subjects demonstrated a slight, non-significant decrease in SMCHD1 mRNA expression 384 
compared to controls (fold-change = 0.94, p = 0.49), with no average difference in allelic 385 
expression of the missense variant compared to the reference allele (p = 0.70), indicating no 386 
change in message stability in arhinia subjects, at least in the available biomaterials (LCLs).  387 
 388 
We next looked for pathways and networks that may be associated with manifestation of arhinia. 389 
When considering all differentially expressed genes following permutation testing (unadjusted p 390 
< 0.05; Supplementary Table 5), we discovered alterations to multiple pathways and human 391 
phenotypes associated with craniofacial development and epigenetic modification. Remarkably, 392 
the strongest human phenotype associated with these genes from ToppGene pathway analysis33 393 
was “depressed nasal tip” (p = 5.1 x10-5 ), as well as related phenotypes such as absent nasal 394 
septal cartilage, semilobar holoprosencephaly, small placenta, and median cleft lip and palate (p 395 
< 0.005). Encouraged by these initial network results across all genes, we next sought greater 396 
specificity of these networks by integrating orthogonal chip and RNAseq data generated from 397 
SMCHD1-null mouse neural stem cells (NSCs)13. From these analyses, we observed a significant 398 
enrichment of down-regulated genes between the human and mouse datasets (p = 0.029), but not 399 
up-regulated genes (p = 0.40), and we identified a high-confidence set of nine overlapping genes 400 
that were down-regulated in both datasets; the same phenotype, “depressed nasal tip”, was more 401 
significant than in the human data alone (p = 2.1 x 10-5). We found these results, and multiple 402 
related human phenotype associations, to be primarily driven by two genes (TGIF1,DOK7), both 403 
of which have already been demonstrated to play a role in craniofacial morphogenesis. DOK7 404 
haploinsufficiency causes fetal akinesia deformation sequence (FADS; OMIM 208150). The 405 
phenotypic spectrum of this disorder includes many features of BAM (depressed nasal bridge, 406 
cleft palate, choanal atresia, microphthalmia, cataract, coloboma, cryptorchidism, and absent 407 
olfactory structures)34, and heterozygous loss-of-function mutations in TGIF1 cause 408 
holoprosencephaly-4 (OMIM 142946), which may include arhinia, microphthalmia, and cleft 409 
palate35. Notably, two additional genes associated with the “depressed nasal tip” phenotype, ICK 410 
and KDM6A (an X-linked gene previously associated with Kabuki syndrome, including multiple 411 
craniofacial anomalies and cleft palate)36,37 were also differentially expressed in the human 412 
dataset. These four genes are therefore rational mechanistic candidates for modifiers of the 413 
arhinia phenotype in the presence of SMCHD1 mutations.  414 
 415 
Prediction of phenotypic outcomes 416 
Among the most striking findings in this study was the demonstration that variants in the same 5’ 417 
constrained region of SMCHD1 are associated with both FSHD2 and arhinia, and the discovery 418 
of an identical amino acid substitution (G137E) within this region that was associated with both 419 
phenotypes18. Methylation assays suggested indistinguishable hypomethylation signatures 420 
between arhinia and FSHD2 probands.  To our knowledge, the comorbid presentation of arhinia 421 
and FSHD2 has never been reported. The lack of previously reported FSHD2 symptoms in 422 
arhinia subjects may be a consequence of the oligogenic architecture of FSHD2, which would 423 
suggest that only a small subset of subjects with arhinia, an already rare condition, would harbor 424 
the requisite genetic architecture at D4Z4 and thus be both at risk and past the average age at 425 
onset for FSHD2.  In addition, features such as facial weakness, which is often one of the first 426 
clinical signs of FSHD2, could easily be overlooked or dismissed in a patient with craniofacial 427 
anomalies who has undergone multiple corrective surgeries. Nonetheless, we performed analyses 428 
comparable to clinical diagnostic testing and found 2 arhinia probands (A1 and E1) with 429 
SMCHD1 variants who met the four critical clinical criteria for susceptibility to FSHD2: 1) an 430 
SMCHD1 pathogenic variant, 2) D4Z4 hypomethylation (bisulfite sequencing [BSS] <25%), 3) a 431 
permissive chromosome 4q haplotype, and 4) an 11-28 D4Z4 repeat unit at the 4q array 432 
(Supplementary Table 4)16,21,38,39. Five other subjects may be at risk for FSHD2 but will require 433 
additional confirmatory clinical testing. We had consent to re-contact both arhinia subjects 434 
meeting FSHD2 clinical criteria, and phenotypic evaluation suggested that at least one subject 435 
had symptoms of FSHD2, proposing yet another mutation site (N139H) common to these two 436 
disorders. Overall, these results suggest that at least two mutations (G137E and N139H), in the 437 
presence of a specific genetic background, can manifest as two divergent clinical phenotypes. 438 
 439 
DISCUSSION   440 
We describe genetic, genomic, and functional evidence that implicate SMCHD1 as the 441 
predominant driver of arhinia in humans. These analyses represent the first evidence of a genetic 442 
cause for this rare craniofacial malformation. Through a large collaborative effort, we were able 443 
to combine data from a sizeable fraction of subjects reported in the literature (24%) and 19 new 444 
subjects, which facilitated the uniform evaluation of the clinical phenotype associated with this 445 
condition. We find that 86% of subjects with arhinia who could be assessed present with the 446 
BAM triad, and that 88% of subjects with BAM harbored SMCHD1 variants. In addition, the 447 
three BAM subjects without an SMCHD1 variant were either part of a consanguineous family, or 448 
exhibited unique phenotypic features (e.g., tracheoesophageal fistula) suggesting alternative 449 
genetic causes in these individuals. Our findings thus suggest a novel role for SMCHD1 in 450 
cranial NCC migration and/or craniofacial placodal development.  451 
 452 
Our genetic observations raise questions concerning potential molecular mechanisms that lead 453 
mutations in the same gene to produce the distinct phenotypes. The fact that all of the arhinia-454 
associated mutations are missense changes rather than truncating mutations, as often seen in 455 
FSHD2, suggests that the arhinia mechanism in humans requires production of a mutant protein 456 
rather than simple loss of function of one allele seen in FSHD2.  However, the overlap of some 457 
arhinia mutations with missense alterations observed in FSHD2 suggests that the mutant protein 458 
that is produced is indeed deficient in some critical function. The FSHD2 hypomethylation 459 
signatures associated with SMCHD1 mutations are demonstrably loss-of-function and consistent 460 
in most circumstances with a haploinsufficiency model, although dominant-negative activity of 461 
the mutant protein has been suggested as the cause of a more severe phenotype in some 462 
cases16,18,20.  We find largely identical methylation patterns at the D4Z4 repeat region on 463 
chromosome 4 in arhinia probands and FSHD2 patients, supporting the view that loss of this 464 
function of SMCHD1 also occurs in arhinia, and so does not in itself explain the difference in 465 
phenotypic outcome. Thus, additional factors must be involved in producing this distinction, 466 
such as interaction at the genetic level with variants at other loci or a function-altering interaction 467 
at the protein level of the mutant SMCHD1 protein.  Indeed, we found that the arhinia-specific 468 
variants tend to cluster on the surface of the protein, potentially facilitating disruption of 469 
interactions with protein partners, either wild-type SMCHD1 or other members of its complexes 470 
(or both). Correspondingly, we found no significant difference in average protein expression 471 
between arhinia probands and unaffected individuals, suggesting that the bioactivity of the 472 
protein is the critical factor in humans rather than the total amount of protein. 473 
 474 
The distinct findings in two model systems reinforce the complexity suggested in humans. The 475 
zebrafish model supports the involvement of loss of function as both MO suppression and 476 
mosaic ablation of smchd1 result in BAM-related phenotypes, the most dramatic of which is the 477 
GnRH terminal nerve projection defect. These results are specific, as these phenotypes are 478 
rescued with full-length human SMCHD1 WT mRNA, but not mRNA containing recurrent 479 
arhinia mutations, and substantial overexpression confers no discernible phenotype.  In the 480 
mouse, complete loss of function has been achieved as homozygosity for an exon 23 Smchd1  481 
nonsense mutation which produces hypomethylation and mid-gestational lethality in females12, 482 
although males are viable.  Heterozygosity for this mutation, like induction of either deletions or 483 
arhinia-relevant point mutations by CRISPR/Cas9, produced no phenotypes in mouse. 484 
Unfortunately, we were unable to replicate in the mouse the heterozygous missense genotype 485 
characteristic of human arhinia (Supplementary Fig. 5). The fact that loss of smchd1 is 486 
sufficient produce BAM-relevant phenotypes in the zebrafish, but loss of Smchd1 in the mouse 487 
does not, reinforces the need to consider genetic and functional interactions of the mutant protein 488 
in causing the human arhinia phenotype.  Notably, both the zebrafish and mouse genomes lack 489 
recognizable orthologs of DUX4, the genetic interactor necessary for the development of 490 
FSHD240,41.  491 
 492 
The complex oligogenic architecture of FSHD2 suggests that only a small fraction of individuals 493 
with arhinia, which is exceedingly rare on its own, will have an SMCHD1 mutation and also 494 
carry a permissive 4q35 haplotype, placing them at risk for FSHD2. Our analyses identified 495 
seven subjects that are potentially at risk for FSHD2, and at least one appears to display 496 
symptoms of the disorder. Nonetheless, one-quarter of individuals who meet genetic diagnostic 497 
criteria for FSHD2 are clinically asymptomatic, indicating that the full complement of genetic 498 
requirements for developing clinical FSHD2 is not yet known42. Like our data, the absence of 499 
arhinia in patients with FSHD2 with SMCHD1 mutations within the constrained ATPase domain 500 
argues that loss of SMCHD1 activity alone is not sufficient to produce a craniofacial phenotype. 501 
The same is true for patients with FSHD2 with mutations in DNA methyltransferase type 3B 502 
(DNMT3B) 43 who have no clinical signs of immunodeficiency, centromeric instability, and 503 
facial anomalies syndrome type 1 (ICF1 [OMIM: 242860])44, the autosomal recessive disorder 504 
associated with mutations at this locus. Within our cohort, we observed multiple family members 505 
harboring SMCHD1 mutations with only mild dysmorphic features or anosmia, and at least one 506 
individual without any dysmorphic features. Given the epigenetic function of SMCHD1, it is 507 
plausible that one or more genetically-interacting loci influence susceptibility to arhinia with the 508 
proximal interactors of SMCHD1 such as TGIF1 and DOK7 representing prime candidates. 509 
Disentangling these genetic mechanisms in conjunction with the biochemical consequences of 510 
SMCHD1 missense mutations in humans and model organisms will be a critical area of further 511 
study, ideally in human tissue of relevance to arhinia and FSHD2 rather than the LCLs currently 512 
available.  513 
 514 
In conclusion, we discovered that rare variants localized to an evolutionarily constrained region 515 
of SMCHD1 are associated with BAM and isolated arhinia. Importantly, during the course of this 516 
study we learned of an independent effort by Gordon and colleagues, who also identified 517 
SMCHD1 missense mutations in arhinia subjects. In correspondence we have compared our 518 
subjects and determined that their study provided an additional 7 subjects that were independent 519 
of our analyses (six overlapped), bringing the total to 45 arhinia subjects, (87%) of whom 520 
harbored a rare missense mutation in SMCHD1. Their analyses also confirmed the SMCHD1 521 
mutation to have occurred de novo in two of the overlapping subjects for which we did not have 522 
parental samples (M1 and AJ1). The molecular mechanism by which such mutations contribute 523 
to arhinia, and what differentiates FSHD2 and arhinia patients, remains unclear, though our 524 
functional modeling suggests that a simple, single locus mechanism is unlikely. Our analyses 525 
thus emphasize yet another example in a growing list of genes in which mutations can give rise 526 
to pleiotropic phenotypes across the spectrum of human anomalies. For SMCHD1, these 527 
phenotypes – a rare muscle disease and now, a severe craniofacial and reproductive disorder - are 528 
perplexingly diverse. Dissecting the genetic and epigenetic factors that determine phenotypic 529 
manifestations will inform both our understanding of the pathogenesis of the arhinia-BAM-530 
FSHD spectra and, more broadly, the genetic and epigenetic architecture of oligogenic disorders.  531 
 532 
 533 
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 570 
Table 1. SMCHD1 mutations observed in arhinia cohort 571 
Chr 
Nucleotide  
change 
Exon 
Inheritance 
 (Sample ID) 
# 
Subjects 
Sample 
 IDs 
AA 
Change 
Gender 
(Sample ID)  
18 c.2666926T>C 3 N/A 1 K1 p.L107P F 
18 c.2666992T>A 3 N/A 1 D1 p.M129K M 
18 c.2667009A>T 3 
De Novo (AF1) 
 N/A (M1) 
2 M1,AF1 p.S135C F 
18 c.2667010G>A 3 
De Novo (I1)  
N/A *(R1) 
2 I1, R1 p.S135N F(R1), M(I1) 
18 c.2667014A>C 3 Father* 1 T1 p.E136D M 
18 c.2667016G>A 3 N/A 1 AG1 p.G137E F 
18 c.2667021A>C 3 
De Novo (A1) 
N/A (Y1) 
2 A1,Y1 p.N139H F(A1,Y1) 
18 c.2667029G>C 3 N/A 3 C1,E1,S1 p.L141F F(S1), M(C1,E1) 
18 c.2667029G>T 3 De Novo 1 V1 p.L141F M 
18 c.2674017 T>G 5 N/A* 1 AB1 p.F171V M 
18 c.2688478C>G 6 De Novo 1 AA1 p. A242G M 
18 c.2694685A>G 8 Mother* 2 O1, O4** p.Q345R F 
18 c.2697032A>G 9 
De Novo 
(X1,AC1,AE1)   
 N/A 
(F1,L1,N1,Z1) 
7 
F1,L1,N1,Z1
X1,AC1,AE1 
p.H348R 
F (L1,X1),                
M(F1,N1,Z1, 
AC1,AE1) 
18 c.2697896A>T 10 Father* 1 AH1 p.Q400L F 
18 c.2697956A>T 10 De Novo 1 P1 p.D420V M 
18 c.2700611G>C 11 N/A 1 W1 p. E473Q M 
18 c.2700837C>A 12 N/A 2 J1,U1 p.T523K F(U1), M(J1) 
18 c.2700840A>G 12 N/A 1 B1 p.N524S M 
   18    c. 2703697G>A 13                 N/A 1 AJ1 p.R552Q M 
*Multiplex family 572 
**Siblings 573 
A rare missense mutation was not identified in SMCHD1 in subjects G1, H1, H2, Q1, AD1, or 574 
AI.  575 
N/A = parental samples not available; AA = amino acid; M = male; F = female. 576 
 577 
Amino acid codes: A=Ala, R=Arg, N=Asn, D=Asp, C=Cys, Q=Gln, E=Glu, G=Gly, H=His, 578 
L=Leu, M=Met, F=Phe, P=Pro, S=Ser, T=Thr, V=Val. 579 
 580 
  581 
FIGURE LEGENDS 582 
 583 
Figure 1.  Phenotypic spectra associated with arhinia 584 
Five representative subjects (a-e) demonstrating complete congenital arhinia and variable ocular 585 
phenotypes: a) Subject V1 (age 2) with left-sided iris coloboma b) Subject AC1 (age 10) has left-586 
sided microphthalmia and bilateral nasolacrimal duct stenosis c) Subject U1 (as a newborn) has 587 
normal eye anatomy and vision, d) Subject O4  (age 16) has right-sided microphthalmia e) 588 
Subject A1 (young child, age unknown) has bilateral colobomatous microphthalmia, cataracts, 589 
and nasolacrimal duct atresia. f-j) All craniofacial radiographic images are from subject V1: f) 590 
Surface rendering reconstruction from a MRI 3D T1 weighted sequence showing complete 591 
absence of the nose (arrow1) g) 3D volume rendering technique (VRT) reconstruction from 592 
spiral CT showing complete absence of nasal bones (arrow) h) Coronal reconstruction from CT 593 
showing absence of nasal septal structures. The maxilla articulates with the nasal process of the 594 
frontal bone (arrow) i) Coronal MRI T2 weighted sequence showing absence of the olfactory 595 
bulb and olfactory sulcus (arrow) j) Midline MRI sagittal T1 weighted sequence. There is a high-596 
arched palate (cleft not visible on this image) and decreased distance between the oral cavity and 597 
the anterior cranial fossa (black arrow). The rudimentary nasopharynx (*) is blind and air-filled.  598 
The pituitary gland (white arrow) appears normal. 599 
 600 
Figure 2. Association analyses for rare mutation burden in arhinia 601 
Manhattan plot and quantile-quantile (q-q) plot demonstrating the significant accumulation of 602 
rare SMCHD1 mutations in subjects with arhinia compared to the ExAC cohort (p = 2.9e-17). 603 
Analyses involved a variant count at each gene for arhinia subjects compared to ExAC controls 604 
(n = 60,706) who presumably do not have arhinia after filtering for allele frequency (MAF < 605 
0.1%), quality (mean depth ≥10; mapping quality ≥10) and predicted function (nonsynonymous, 606 
splice site, and frameshift mutations). Any gene with at least one mutation passing these criteria 607 
was included in the analysis (n = 22,445 genes). Genome-wide significance threshold was p < 608 
2.2x10-6 following Bonferroni correction (red line) and only SMCHD1 achieved this threshold.  609 
 610 
 611 
Figure 3.  Arhinia mutations occur near the 5’ GHKL-type ATPase domain  612 
a) The distribution of arhinia mutations across SMCHD1 is tightly clustered between exons 3-12 613 
of the gene compared to b) the distribution of variants observed in FSHD2 subjects and c) ExAC 614 
controls. FSHD2 subjects were taken from the Leiden Open Variation Database (LOVD 3.0)45. 615 
Constraint analysis as described by Daly and colleagues10 revealed that while the gene displays 616 
significant overall intolerance to deleterious mutations (p = 0.016), this significance is almost 617 
entirely driven by constraint across the first 19 exons of SMCHD1 (Χ2 = 37.73; p = 8.12x10-10), 618 
which includes the GHKL-type ATPase domain, whereas the region from exons 20-48 are not 619 
constrained (Χ2 = 0.87; p = 0.35). Figures were modified from the cBioPortal Mutation Mapper 620 
software v1.0.1 (http://www.cbioportal.org/mutation_mapper.jsp)46,47  621 
 622 
Figure 4. DNA methylation analysis of D4Z4 repeats   623 
a) Bisulfite sequencing (BSS) of the chromosome 4q and 10q D4Z4 repeats identifies DNA 624 
hypomethylation consistent with dominant SMCHD1 hypomorphic mutations found in FSHD2 625 
patients.  A total of 52 CpGs were analyzed, arranged linearly from left to right, for 12 clones 626 
arranged top to bottom, each representing an independent chromosome analyzed.  Each predicted 627 
CpG is represented by a box, with red boxes indicating methylated CpGs and blue boxes 628 
indicating unmethylated CpGs.  b) Cartoon of the chromosome 4q and 10q D4Z4 macrosatellites 629 
that vary in repeat units (RU) from 1 to ~120 RUs.  The region analyzed by BSS in each RU is 630 
indicated by a green bar. *FSHD2 requires a mutation in SMCHD1 combined with at least 1 631 
chromosome 4q D4Z4 array ranging in size between 11-28 RUs and a permissive A-type 4q 632 
subtelomere. c) BSS observed 75% of arhinia probands with SMCHD1 mutations that could be 633 
tested due to available material had D4Z4 hypomethylation characteristic of FSHD2, while the 634 
single proband tested without a SMCHD1 mutation showed a normal methylation pattern. BSS 635 
was measured from the lowest quartile as previously described21 and a methylation rate of <25% 636 
was considered consistent with hypomethylation observed in FSHD2. See Supplementary 637 
Table 4 for further details on individual methylation status. 638 
 639 
Figure 5. In vivo modeling of smchd1 in zebrafish demonstrates craniofacial and GnRH 640 
phenotypes relevant to congenital arhinia 641 
a.) Suppression of smchd1 results in altered cartilage structures in 3 day post-fertilization (dpf) -642 
1.4col1a1:egfp larvae. Representative ventral images; smchd1 morphants and F0 mutant larvae 643 
display a reduction in the size of the ethmoid plate (ep, as measured with solid white arrows); 644 
and abnormal jaw structures including a broadened ceratohyal angle (ch, dashed white line), and 645 
reduction in the number of ceratobranchial arches (cb, asterisks). Scale bar, 200m b) 646 
Quantification of ethmoid plate width measured on ventral images. The furthest distal width (a, 647 
left panel a) was normalized to the width at the ethmoid plate-trabecula junction (b, left panel a). 648 
c) Loss of smchd1 results in a decreased eye size; lateral bright-field images of representative 649 
3dpf control, morphant, and CRISPR/Cas9 larvae are shown. Scale bar = 300m. d) 650 
Quantification of eye size area in larval batches (indicated with dashed white circle in panel c). 651 
e) Immunostaining of gonadotropin releasing hormone (GnRH) neurons in 1.5 dpf embryos with 652 
a pan-GnRH antibody shows shorter terminal nerve (tn) projections from the olfactory bulb (ob) 653 
in smchd1 models. Representative ventral views are shown; h, hypothalamus; scale bar, 100m; 654 
Dashed white boxes are zoomed to show tn projections in the insets; dashed white lines (insets) 655 
indicate tn length measurement starting proximal to the ob, and extending to the tip of the tn. f) 656 
In vivo complementation assay of missense SMCHD1 variants using GnRH tn length as a 657 
phenotypic readout. S135C, L141F, and H348R are recurrent mutations in arhinia cases; P690S 658 
is associated with FSHD218 V708I (rs2276092) is a common variant in ExAC and is a negative 659 
control for the assay. Orientation indicated (panels a and e) with arrows pointing to anterior (A), 660 
posterior (P), left (L) and right (R). Statistical significance is indicated with *** (p<0.0001), ** 661 
(p<0.01), or *(p<0.05); g, guide RNA; NS, not significant. n=19-50 embryos/injection (panel b); 662 
n=28-59 embryos/injection (panel d); n=18-20 embryos/injection (panel f) with masked scoring; 663 
all experiments were repeated. Error bars indicate standard error of the mean.  664 
  665 
Figure 6: SMCHD1 protein modeling.  666 
Protein modeling predicts that arhinia mutations were more likely to occur on the surface of 667 
Smchd1 and disrupt a binding surface compared to the distribution of FSHD2 mutations. A) 668 
Homology model of the N-terminal region of SMCHD1 generated with Phyre232 with residues 669 
mutated in arhinia (red) and FSHD2 (blue). All of the top 20 structural templates had GHKL 670 
domains: 16 were Hsp90 structures, two were mismatch repair proteins (MutL/Mlh1) and two 671 
were type II topoisomerases. Only those residues modeled with high confidence are shown (115-672 
295; 314-439; 458-491; 504-535; 552-573). B) Comparison of predicted relative solvent 673 
accessibility values for residues in the N-terminal region of SMCHD1 mutated in arhinia and 674 
FSHD2. Three different predictive methods were used: NetsurfP48, I-TASSER49 and SPIDER50. 675 
Residues mutated in both disorders (136-137) are excluded in this analysis. P-values are 676 
calculated with the Wilcoxon rank-sum test. Boxes represent quartile distributions. 677 
 678 
 679 
ONLINE METHODS 680 
 681 
Research Subject Enrollment. We collected existing DNA or blood samples from 38 subjects 682 
with arhinia (22 male, 16 female). Whenever possible, DNA was also collected from family 683 
members. Phenotypic information was obtained via questionnaires completed by patients, 684 
parents, or referring physicians and confirmed by review of official medical records and 685 
consultation with the referring physician. Note that reproductive axis dysfunction could not be 686 
determined in pre-pubertal girls or in pre-pubertal boys without congenital microphallus or 687 
cryptorchidism. All research was approved by the Institutional Review Board of Partners 688 
Healthcare and a subset of families consented to publication of photographs (Figure 1).  689 
 690 
Whole-Exome Sequencing (WES).  We performed WES on 26 total probands with arhinia (22 691 
in initial round and 4 that failed targeted sequencing) and 12 family members. The majority of 692 
subjects (n = 29) were sequenced at the Broad Institute (Cambridge, MA, USA), 693 
including 21 independent subjects and 1 set of affected siblings from a consanguineous family. 694 
We also sequenced 6 unaffected available family members from these subjects at the Broad 695 
Institute (families A, D, E; see Supplementary Fig. 1). We collected another two sporadic 696 
subjects, one trio (family V) and a mother-proband pair (family U), that had previous WES 697 
sequencing from the University of Zurich (Zurich, Zurich, Switzerland). We also collected a trio 698 
(family T) that had previously undergone WES by GeneDx (Gaithersburg, MD, USA) and 699 
contained an affected proband who also had a deceased great aunt with arhinia and coloboma. 700 
We finally received exome results for a subject (AJ1) with arhinia from the Department of 701 
Human Genetics at Nagasaki University. All exomes except sample AJ1 were aligned in house 702 
with BWA-MEM v.0.7.10 to GRCh37 and underwent joint variant calling by GATK51 following 703 
best practice methods52,53. Familial relationships were confirmed by KING v1.454 and variants 704 
were annotated with Annovar v.2016-02-0155 against the refseq annotation of the genome 705 
(http://www.ncbi.nlm.nih.gov/refseq/).  706 
 707 
Whole-Genome Sequencing (WGS). We obtained samples from 4 members of 708 
multigenerational family O 6,7 (see Supplementary Fig.1) and performed whole-genome deep 709 
WGS to 30X average coverage on the Illumina X Ten platform. Family O had multiple 710 
individuals with craniofacial abnormalities beyond the proband’s arhinia, including a deceased 711 
maternal-half aunt with arhinia, a sister with arhinia, a mother with anosmia and subtle nasal and 712 
dental anomalies, and a maternal grandmother with mild nasal and dental anomalies. Note that 713 
samples from the affected sister, unaffected brother, and unaffected maternal half-aunt were 714 
obtained after WGS had been completed and were therefore screened for the p.Q345R variant by 715 
targeted sequencing. Variants were aligned with BWA-MEM v.7.7 to GRCh37 and GATK was 716 
used to call single nucleotide variants (SNVs) as described above.    717 
 718 
Genetic Association Analyses.  We compared the genic burden of rare, nonsynonymous 719 
variants detected by WES in independent arhinia subjects from our cohort (n = 29; one affected 720 
subject [brother] selected from consanguineous sibship) with WES data from over 60,706 721 
controls in the the Exome Aggregation Consortium8,9 (ExAC; http://exac.broadinstitute.org/). 722 
Analyses were restricted to include variants that passed the following criteria: 1) high quality 723 
(GATK Filter=PASS), 2) rare  (ExAC minor allele frequency [MAF] < 0.1%), 3) mean depth ≥ 724 
10 reads, 4) a mapping quality ≥ 10, and 5) predicted to be nonsynonymous, to alter splicing, or 725 
to cause a frameshift. As there was no gender bias among our arhinia subjects to suggest sex-726 
linkage (42% female), and we could not ascertain gender from the ExAC database, analyses were 727 
restricted to autosomes. Counts between ExAC and the arhinia cohort were compared by a Fisher 728 
exact test. Results were visualized as a Manhattan and QQ plot created by the R package 729 
qqman56.  730 
 731 
Targeted Sequencing. Variants of interest, as determined by our WES and WGS gene 732 
association analysis, were subsequently confirmed by Sanger sequencing in all subjects except 733 
T1, as DNA was not available (we are getting DNA). Analyses of these subjects demonstrated a 734 
significant aggregation of rare mutations in SMCHD1 restricted to exons 3, 8-10, 12, and 13.  We 735 
therefore performed targeted sequencing of these exons in all additional subjects (n = 12) using 736 
the primers below and subjects that failed this targeted sequencing (n=4) were sent for WES as 737 
described above.  738 
 739 
Exon Primer Sequence 5'-3' 
Exon 3 fwd TGCTTACAGGTAGATGATTGGG 
Exon 3 rev GGAATGGGATACGTAATCAGG 
Exon 6&7 fwd TTAACACTGAATACAAGTGCAATG 
Exon 6&7 rev TTCATACTTTCAAGTTAAGTTCTGTCC 
Exon 8 fwd TGTATTGGGCCAGTTTCCTC 
Exon 8 rev CCTGTGCCTCAAATAATGCTC 
Exon 9 fwd AAATGCTTAATAAAGTGCTTGATACC 
Exon 9 rev TTTATTATCCTGAGTCATTTGGAAC 
Exon 10 fwd TGTCCTTCAGCTCTGATTTGC 
Exon 10 rev GAGAAGACAAGGGAACATATAAAGG 
Exon 11 fwd TGTGTTTGTTTCATTATTTCTCACA 
Exon 11 rev GGAGGAGTACACCAGTCAAAGC 
Exon 12 fwd CAGCTAGAGGGAAAAGGCCT 
Exon 12 rev TGTGAACACTTGACTGCTCA 
Exon 13 fwd GGTAATGCATTTGTTTGAAATATCC 
Exon 13 rev CTTCATGAAATGTGAGAATGGG 
 740 
 741 
Inheritance Testing: For samples with a predicted de novo variant without WES we confirmed 742 
familial relationships by determining repeat length of 10 STS markers (d15s205, d12s78, 743 
d4s402, d13s170, d4s414, d22s283, d13s159, d2s337, d3s1267, d12s86). Inheritance of markers 744 
was checked in each proband and proper parental inheritance was confirmed in all cases. 745 
Inheritance for a single proband (P1) was confirmed in a similar manner at the University of 746 
Edinburgh with the following nine markers: cfstr1, d7s480, dxs1214, amel, nr2e3_22, d4s2366, 747 
i1cahd, d5s629, d5s823.   748 
 749 
Transcriptome Sequencing (RNAseq). Total RNA of ~1 million cells was extracted 750 
from EBV-transformed lymphoblastoid cell line (LCLs) using TRIzol® (Invitrogen) followed by 751 
RNeasy® Mini Kit (Qiagen) column purification. RNAseq libraries were prepared using the 752 
Illumina TruSeq kit and manufacturer’s instructions, as described57,58. Libraries were 753 
multiplexed, pooled and sequenced on multiple lanes of an Illumina HiSeq2500, generating an 754 
average of 33 million paired-end reads of 76 bp. Quality checking of sequence reads was 755 
assessed by fastQC (v. 0.10.1) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 756 
Next, sequence reads were aligned to human reference genome Ensembl GRCh37 (v. 71) using 757 
GSNAP (v. 12-19-2014) at its default parameter setting59. Quality checking of alignments was 758 
assessed by a custom script utilizing Picard Tools (http://broadinstitute.github.io/picard/) , 759 
RNASeQC60, RSeQC61 and SamTools62. Gene level counts were tabulated using BedTools’s 760 
multibamcov algorithm (v. 2.17.0)63 on unique alignments for each library at all Ensembl genes 761 
(GRCh37 v.71).  We found the threshold to detect expressed genes to be at least six uniquely 762 
mapped reads by relying on analysis of External RNA Controls Consortium (ERCC) spike-ins as 763 
we have previously described57.  After filtering out short genes (transcript lengths < 250 nt) and 764 
rRNA and tRNA genes, only the 15,936 genes that met the detection threshold in all case 765 
samples or all control samples were kept for further analysis. To account for the effect of the 766 
covariance among family members, a generalized linear-mixed model (GLMM) approach was 767 
used. For this task, a mixed model package, lme4 (v. 1.1.10)64 was employed in R (v. 3.2.2). 768 
Specifically, gene-level expression data across samples as raw counts was fitted to a following 769 
GLMM based on a Poisson-lognormal approach , where 770 
condition is a fixed factor that describes a binary disease status of an individual, familyId is a 771 
random factor that accounts for similarity in expression due to shared genetic background and 772 
obsId is a random factor that accounts for individual-level random effects. This model converged 773 
on 15,478 genes. An evolutionary constrained gene list was retrieved from the ExAC database 774 
(v. 0.3 release 3-16-2015), where constrained genes were defined to be those with a probability 775 
of being intolerant to loss of function mutations ≥ 0.9. A protein-protein interaction network of 776 
differentially expressed genes (nominal p < 0.05) was constructed based on physical interaction 777 
data from the BioGRID database (v 3.4.135)65.  The resulting network contained 1,069 proteins 778 
and 2,593 pair-wise interactions in which a protein had 4.86 connections (degrees) on average. 779 
We defined hub proteins to be in the top 5th percentile of degree distribution in this network, 780 
which corresponds to 17 connections or more.  781 
 782 
Western Blot: Protein was harvested from 1 million LCLs in 23 total subjects: 10 subjects with 783 
arhinia harboring presumably pathogenic SMCHD1 variants, 11 unaffected family members 784 
without SMCHD1 mutations, and two family members with a mutation in SMCHD1 and anosmia 785 
or a hypoplastic nose (AH3 and AH5, respectively; Supplemental Fig. 9). Protein extraction 786 
was performed with the  following procedure:  1) Cells were washed in 1x PBS and lysed in 300 787 
ul ice-cold 1 x RIPA buffer (http://www.bio-world.com/productinfo/4_62_465/7465/RIPA-788 
Buffer-X-pH.html) supplemented with 5 mM PMSF. 2) After 30 min. incubation on ice, cell 789 
lysates were cleared by centrifugation (15G, 15 min., 4*C) and soluble proteins concentration 790 
was assayed with BCA reagent 791 
condition+ 1| familyId( ) + 1|obsId( )
(https://www.thermofisher.com/order/catalog/product/23225#/23225). Extracted proteins 792 
(15-30 ul/sample) were next separated by a 8% sodium dodecyl sulfate polyacrylamide gel 793 
electrophoresis (SDS-PAGE;Bio-Rad MiniProtean 3 Cell, 2 hr 15 mA)  and transferred onto a 794 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad cat#1620174) using liquid transfer system  795 
(Bio-Rad Ready Gel Cell) at 4*C, 10V for 16 hrs. Western plotting was performed using two 796 
sets of SMCHD1 antibodies: 1) Bethyl Laboratories A302-872A-M (anti-SMCHD1, C-797 
terminus); 2) Abcam ab122555 (anti-SMCHD1, N-terminus). We used two loading control 798 
antibodies: 1) Abcam ab6046 (beta-Tubulin load control) 2) Abcam ab8227 (beta-Actin load 799 
control). Antibody dilutions were used as recommended by manufacturer. Primary antibodies 800 
were diluted in tris-buffered saline and tween 20 (TBST) buffer and 1% BSA, secondary HRP-801 
conjugated antibody (1:20,000 dilution) in TBST without BSA. Membrane was cut alongside 75 802 
kDa marker (BioRad Precision Plus Protein standards cat# 161-0375) and the upper part was 803 
used for blotting SMCHD1 (MW=250 kDa), while the lower part for blotting beta-Tubulin 804 
(MW=50 kDa) and beta-Actin (MW=42 kDa) controls. Blotting with primary antibody was 805 
carried out overnight at 4*C on a rocking platform, followed by three 10 min. washes in TBST at 806 
room temperature. Blotting with secondary antibody was carried out at room temperature for 1 807 
hr, followed by three 10 min. washes in TBST. Re-blotting of SMCHD1 with an alternative 808 
antibody, the previously used primary antibody was stripped off with mild stripping buffer, as 809 
described: http://www.abcam.com/ps/pdf/protocols/stripping%20for%20reprobing.pdf.  Western 810 
blot were luminesced with ECL reagent (Bio-Rad cat# 170-5060) and developed with the 811 
ChemiDoc MP system (http://www.bio-rad.com/en-us/product/chemidoc-imaging-812 
systems/chemidoc-mp-system). Automated protein quantification was done using Image Lab 813 
5.2.1 software (BioRad). 814 
 815 
 816 
CRISPR/Cas9 Genome Editing in Mouse Embryos.  To generate mouse embryos carrying the 817 
p.Leu141Phe disease associated missense variant in Smchd1, a double stranded DNA oligomer 818 
(CCTTTGCGTAAGTAACCTGCTC) that provides a template for the guide RNA sequence was 819 
cloned into px461. The full gRNA template sequence is amplified from the resulting px461 clone 820 
using universal reverse primer and T7 tagged forward primers. The guide RNA PCR template is 821 
used for in vitro RNA synthesis using T7 RNA polymerase(Neb), and the RNA template is 822 
subsequently purified using RNeasy mini kit (Qiagen) purification columns. Cas9 mRNA was 823 
procured from Tebu Bioscience. The wild-type and mutant repair templates (chr17:71,463,705-824 
71,463,818 GRCm38) are synthesized as 114bp ultramers bearing the desired sequence change 825 
from IDT. The injection mix contains Cas9 mRNA (50ng/ul), guide RNA (25ng/ul) and repair 826 
template DNA (150ng/ul). Injections are performed in mouse zygotes and the embryos are later 827 
harvested for analysis at 11.5 and 13.5 dpc stage of embryonic development. 828 
 829 
Optical Projection Tomography. Whole mouse embryos were mounted in 1% agarose, 830 
dehydrated in methanol and then cleared overnight in BABB (1 part Benzyl Alcohol: 2 parts 831 
Benzyl Benzoate). The sample was then imaged using a Bioptonics OPT Scanner 3001 832 
(Bioptonics, UK) using tissue autofluorescence (excitation 425nm/emmision 475nm) to capture 833 
the anatomy.  The resulting images were reconstructed using Bioptonics propriatory software, 834 
automatically thresholded and merged to a single 3D image output using Bioptonics Viewer 835 
software. 836 
 837 
DNA methylation analysis. The DNA methylation status of the D4Z4 region was assayed as 838 
previously described21.  Bisulfite conversion was performed on 1 μg of genomic DNA using the 839 
EpiTect Bisulfite Kit (Qiagen) per manufacturer’s instructions, and 200 ng of converted genomic 840 
DNA was used for PCR. Bisulfite sequencing (BSS) analysis of 52 CpGs in the DUX4 promoter 841 
region of the 4q and 10q D4Z4 repeats was performed using primers BSS167F: 842 
TTTTGGGTTGGGTGGAGATTTT and BSS1036R: AACACCRTACCRAACTTACACCCTT, 843 
followed by nested PCR with BSS475F: TTAGGAGGGAGGGAGGGAGGTAG and 844 
BSS1036R using 10% of the first PCR product.  PCR products were cloned into the pGEM-T 845 
Easy vector (Promega), sequenced, and analyzed using web-based analysis software BISMA 846 
(http://biochem.jacobs-university.de/BDPC/BISMA/)66 with the default parameters. Standard 847 
genomic PCR was performed on non-converted DNA to identify the 4qA, 4qA-L and 4qB 848 
chromosome67.  Specific 4q and 10q haplotypes were identified and assigned as previously 849 
described68,69.  The presence of the DUX4 polyadenylation site was determined by BS-PCR as 850 
previously described42. 851 
 852 
Determination of 4q35 and 10q26 D4Z4 array sizes. Peripheral blood leukocytes were 853 
embedded in agarose plugs and digested with three different restriction enzymes (EcoRI, 854 
EcoRI/BlnI, and XapI).  Restriction fragments were separated by pulse field gel electrophoresis 855 
(PFGE) and sized and visualized by Southern blot with a p13E-11 probe, and in some subjects, a 856 
D4Z4 probe for confirmation70.    857 
 858 
Gene suppression and in vivo complementation of zebrafish embryos. Splice blocking 859 
morpholinos (MO)s targeting the Danio rerio smchd1 exon 3 splice donor (e3i3; 5’-860 
AGGTGTGATTTCAGACTTACGCAAC-3’) or exon 5 splice donor (e5i5; 5’- 861 
TGATTATGAAGACCGCACCTTTGAA-3’) were designed and synthesized by Gene Tools 862 
LLC (Philomath, Oregon). To determine the optimal MO dose for in vivo complementation 863 
studies, we injected increasing doses (3 ng, 6 ng, and 9 ng of each MO; 1 nl MO injected per 864 
embryo; 1-2 cell stage) into -1.4col1a1:egfp71 embryos harvested from natural mating of 865 
heterozygous transgenic adults maintained on an AB background. To determine MO efficiency, 866 
we used Trizol (ThermoFisher) to extract total RNA from embryos at 1 day post-fertilization 867 
(dpf) according to manufacturer’s instructions. Resulting total RNA was reverse transcribed into 868 
cDNA using the Superscript III Reverse Transcriptase kit (ThermoFisher), and was used as 869 
template in RT-PCR reactions to amplify regions flanking MO target sites. RT-PCR products 870 
were gel-purified using the QIAquick gel extraction kit (Qiagen), cloned (TOPO-TA; 871 
Invitrogen), and plasmid purified from individual colonies was Sanger sequenced according to 872 
standard protocols to identify the precise alteration of endogenous transcript. For rescue 873 
experiments, a wild-type (WT) human SMCHD1 ORF (NM_015295) construct was obtained 874 
commercially (OriGene Technologies) and subcloned into the pCS2+ vector. Point mutations 875 
were introduced into pCS2+ vectors as described72 and all vectors were sequence confirmed. WT 876 
and variant SMCHD1 constructs were linearized with NotI, and mRNA was transcribed using the 877 
mMessage mMachine kit SP6 transcription kit (ThermoFisher). Unless otherwise noted, 9 ng 878 
MO (either e3i3 or e5i5) was used in parallel or in combination with 25 pg SMCHD1 mRNA for 879 
in vivo complementation studies. 880 
 881 
 882 
CRISPR/Cas9 genome editing in zebrafish embryos. We used CHOPCHOP 883 
(http://chopchop.cbu.uib.no/) to identify a guide (g)RNA targeting sequence a within the smchd1 884 
coding regions (5’ GAGATGTCGAAAGTCCGCGG 3’). Guide RNAs were in vitro transcribed 885 
using the GeneArt precision gRNA synthesis kit (ThermoFisher) according to manufacturer’s 886 
instructions. Zebrafish embryos were obtained from -1.4col1a1:egfp embryos harvested from 887 
natural mating of heterozygous transgenic adults maintained on an AB background; 1 nl of 888 
injection cocktail containing 100 pg/nl gRNA and 200 pg/nl Cas9 protein (PNA Bio) were 889 
injected into the cell of embryos at the one-cell stage. To determine targeting efficiency in 890 
founder (F0) mutants, we extracted genomic DNA from 2 dpf embryos and PCR-amplified the 891 
region flanking the gRNA target site. PCR products were denatured, reannealed slowly and 892 
separated on a 15% TBE 1.0 mm precast polyacrylamide gel; it was incubated in ethidium 893 
bromide and imaged on a ChemiDoc system (BioRad) to visualize hetero/homoduplexes. To 894 
estimate the percent mosaicism of smchd1 F0 mutants (n=5), PCR products were gel purified 895 
(Qiagen), and cloned into a TOPO-TA vector (ThermoFisher). Plasmid was prepped from 896 
individual colonies (n=10-12 colonies/embryo), and Sanger sequenced according to standard 897 
procedures. 898 
 899 
Phenotypic analyses in zebrafish. To study craniofacial structures (cartilage or eye 900 
development), larval batches were reared at 280C and imaged live at 3 dpf using the Vertebrate 901 
Automated Screening Technology Bioimager (VAST; software version 1.2.2.8; Union 902 
Biometrica) mounted on an AxioScope A1 (Zeiss) microscope using an Axiocam 503 903 
monochromatic camera and Zen Pro 2012 software (Zeiss). Fluorescence imaging of GFP 904 
positive cells on ventrally positioned larvae was conducted as described73. In parallel, we 905 
obtained lateral bright-field images of whole larvae using the VAST onboard camera. To 906 
evaluate gonadotropin-releasing hormone (GnRH) neurons, 1.5 dpf embryos were dechorionated 907 
and fixed in a solution of 4% paraformaldehyde (PFA) and 7% picric acid for 2 hours at room 908 
temperature. Embryos were then washed with a solution of phosphate buffered saline with 0.1% 909 
Triton X-100 (PBS-T) and stored at 40C until staining. For whole-mount immunostaining, 910 
embryos were washed briefly with 0.1% trypsin in PBS; washed in PBS-T; and dehydrated at -911 
200C in pre-chilled 100% acetone for 15 min. Next, embryos were washed in PBS-T; blocked in 912 
a solution of 2% BSA, 1% DMSO, 0.5% Triton-X100, and 5% calf serum for 1 hour at room 913 
temperature. We used rabbit anti-GnRH antibody (1:500 dilution; Sigma) for primary detection. 914 
Following overnight incubation of primary antibody, we washed with blocking solution, and 915 
incubated with AlexaFluor 555 anti-rabbit secondary antibody (1:500; ThermoFisher) for 2 hours 916 
at room temperature. Images were acquired manually with an AxioZoom.V16 microscope and 917 
Axiocam 503 monochromatic camera, and were z-stacked using Zen Pro 2012 software (Zeiss). 918 
Cartilage structure, eye area, and GnRH neuron projection length was measured using ImageJ 919 
software (NIH); pairwise comparisons to determine statistical significance were calculated using 920 
a student’s t-test. For ceratobranchial pair counts, we used a 2 test to determine statistical 921 
significance. All experiments were repeated at least twice. 922 
 923 
 924 
 925 
 926 
 927 
 928 
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